- Notes in bold indicate new information (to my knowledge)
- INFI will host a CC on June 1st to review pipeline and discuss ASCO abstracts that will be released May 18th
- Accruing patients in the pancreatic cancer trial for IPI-926 is a top priority. Company believes that they will complete enrollment by ye2011.
- Also will initiate investigator-sponsored trial program for IPI-926 for range of potential indications and in combination w/ commonly used and emerging treatments. First is head and neck cancer p1 combo w/ erbitux in 24 pts, expect others this year
- ASCO June 2011: p1b data for IPI-926, including pancreatic cancer patients and followup data from basal cell carcinoma pts
- ASCO June 2011: IPI-504 combo w/ taxotere data
- In the process of evaluating data from IPI-493 p1 trials, on track for HSP90 inhibitor program udpdate by this summer
- $91.2m cash on hand 3/31/11
- $24.3m r&d expenses in 1q2011, up $5m from 1q2010
- net loss $2.3m 1q2011
- expect cash burn $30-40m in 2011. $90-95m rev (reimbursed expenses $85m and recognition of deferred upfront fees). $120-130m expenses, net loss $30-40m. ye cash $60-70m w/o $50m line of credit. Expect to access credit line in full by end of 1q2012
- cash runway into 2014
- q&a session:
- Only one question re revenue components (analyst wasn't listening to CFO earlier on the call I guess)